Corporate

Hikma appoints Dr Shahin Fesharaki as Chief Scientific Officer and Global Head of R&D

London, 5 August 2019 – Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1/stable Moody’s and BB+/positive S&P), the multinational generic pharmaceutical company, today announces that Dr Shahin Fesharaki joins the company as Chief Scientific Officer and Global Head of Research & Development (R&D). Dr Fesharaki will have responsibility for all aspects of the company’s R&D and becomes a member of Hikma’s Executive Committee, reporting into the CEO, Siggi Olafsson.

“Shahin has a great industry track record of developing and commercialising hundreds of new products including Abbreviated New Drug Applications (ANDAs), first-to-file and first-to-market opportunities,” said Siggi Olafsson, Chief Executive Officer of Hikma.  “Filling our pipeline with products needed by our customers and patients is a key aspect of our strategy, and the appointment of Shahin is a significant step forward in successfully delivering on this strategy.”

Dr Fesharaki brings more than 25 years of extensive development experience in both generic and branded pharmaceuticals across a broad range of technologies and dosage forms. He has held senior R&D leadership positions at some of the most successful generic pharmaceutical companies including Watson, Apotex and more recently Actavis where he led the global R&D operations function. 

“I’m proud to be joining the Hikma team at such a pivotal time in the company’s growth journey,” said Dr Fesharaki.  “Hikma’s commitment to quality is one that I share, and I am eager to join the team and lead the R&D function forward with new and needed products that will benefit patients around the world.”